Pyruvate Kinase
EstablishedPyruvate kinase deficiency causes chronic hemolytic anemia, now treatable with a novel oral enzyme activator (mitapivat).
This enzyme helps red blood cells make energy. Without enough of it, cells break down too easily, causing lifelong anemia. A new pill medication was recently approved that directly boosts this enzyme's activity — the first real treatment beyond blood transfusions and spleen removal for this condition.
Pyruvate kinase is a key enzyme in red blood cell glycolysis (energy metabolism); its deficiency is a rare inherited cause of chronic hemolytic anemia due to impaired red cell energy production.
Low pyruvate kinase enzyme activity confirms pyruvate kinase deficiency in a patient with chronic non-spherocytic hemolytic anemia, jaundice, and splenomegaly, typically presenting from infancy through adulthood with variable severity.
Measured via red blood cell enzyme activity assay; genetic testing of the PKLR gene can confirm diagnosis and inform genetic counseling, since the condition is autosomal recessive.
A specific pyruvate kinase activator drug (mitapivat) was approved in recent years, giving this previously untreatable enzyme deficiency an actual disease-modifying oral therapy for the first time, rather than relying solely on supportive care (transfusions, splenectomy) as in the past.
Represents a rare case of a previously untreatable enzyme deficiency gaining a genuine disease-modifying drug.
- General hematology reference literature on pyruvate kinase deficiency and mitapivat as a novel enzyme activator therapy.